Page 8 - Dr Reddy’s Laboratories

Russia to jointly produce Sputnik V vaccine for Covid with India: Envoy

Russian envoy to India Nikolay Kudashev on Monday said Moscow will jointly produce the Sputnik V vaccine for COVID-19 along with New Delhi

Pfizer moves US court against Aurobindo Pharma, Dr Reddy's on cancer drug

Pfizer Inc alleged that the drug makers were planning separately to come out with generic versions of its blockbuster multi-billion dollar drug Ibrance (palbociclib) before expiration of its patent

DCGI rejects DRL's proposal, denies full marketing rights for Remdesivir

Emergency use authorisation to continue; recently, WHO had raised doubts about efficacy of drug in treatment of Covid-19 patients

Dr Reddy's partners Dept of Biotech for vaccine clinical trials in India

Dr Reddy's Laboratories Ltd announced its partnership with BIRAC, DBT, for advisory support on clinical trials of Sputnik V vaccine in India

Dr Reddy's Q2 PAT down 30% to Rs 762 crore from Rs 1,092 cr year-ago

The PAT of Dr Reddys Laboratories for the quarter ended on September 30, 2020, was down by 30 per cent at Rs 762.3 crore compared to Rs 1,092.5 crore during the corresponding quarter last fiscal

USFDA approves Remdesivir as first Covid-19 therapy amid WHO reservations

Approval unlikely to increase prices immediately as Gilead has said licenses are royalty-free until the end of the health emergency

Dr Reddy's Labs isolates data centre services due to cyber attack

Dr Reddy's Laboratories on Thursday said it has isolated all data centre services following a cyber-attack

Dr Reddy's launches Famotidine generic product in US to treat acidity

Dr Reddy's Laboratories on Tuesday said it has launched over-the-counter (OTC) drug Famotidine tablets, used to treat gastroesophageal reflux disease, in the American market. The company has launched the product, which is equivalent to Johnson & Johnson's Pepcid AC, in the US after getting approval from the US Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a statement. Famotidine tablets are used to prevent and relieve heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain food and beverages. This launch will help us fulfil an important therapy gap created in antacids market due to Ranitidine withdrawal," Dr Reddy's Laboratories North America Generics CEO Marc Kikuchi said. The Pepcid AC brand and generic versions had US sales of around USD 211 million for the 12 months ended in August 2020.

Dr Reddy's gets DCGI nod to conduct Covid-19 vaccine phase 2/3 human trails

Dr Reddy's and Russian Direct Investment Fund on Saturday announced that they have received approval from DCGI to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India

Panel urges granting Dr Reddy's permission for Russia vaccine phase 2 trial

The SEC had on October 5 asked the firm to re-apply stating it will have to conduct both phase 2 and 3 clinical trials and cannot directly hold phase 3 trial for the vaccine in India

Dr Reddy's: Progress in Covid vaccine trials to boost firm's growth outlook

Good momentum in US and domestic sales, along with Covid-19 treatment portfolio is already driving analysts to upgrade earnings estimates

Indian samples of global Covid-19 vaccines need to be larger: Experts

Indian players like Bharat Biotech and Zydus Cadila ready for large-scale phase-3 trials

India declines proposal to test Sputnik-V Covid-19 vaccine in large study

India is expected to overtake the United States over the next several weeks as the country with the world's largest number of cases

Dr Reddy's asked to re-submit Russian vaccine phase-3 trial application

Health Secy says a vaccine should be available in first quarter of next year if everything goes according to plan

Dr Reddy's asked to resubmit application for trials of Russian vaccine

An expert panel at CDSCO has asked Dr Reddy's Laboratories to submit a revised protocol for conducting both phase 2 and phase 3 human clinical trials for the Russian vaccine against Covid-19

Dr Reddy's says it aims to cut greenhouse gas emissions by 55% by 2030

Dr Reddy's Laboratories on Monday said it has committed to reduce its greenhouse gas emissions by 55 per cent by 2030. The Hyderabad-based drug major has joined hands with the Science Based Targets initiative (SBTi), thus becoming the first Indian and the third Asian pharmaceutical company to have set its science-based targets to further minimise environmental impact, Dr Reddy's Laboratories said in a statement. The company has committed to reducing its Scope 1 and 2 greenhouse gas (GHG) emissions by 55 per cent by 2030 from 2017-18 base year, which are in line with the latest climate science of limiting global warming to below 1.5C above pre-industrial levels, it added. "Continuous improvement in our environmental performance is a notable aspect of our sustainability journey. We are delighted to join SBTi in taking a science-based approach to set our GHG emission reduction targets and accelerating our efforts to creating a positive impact on our planet," Dr Reddy's Laboratories ...

Dr Reddy's yet to apply for clinical trials of Sputnik V Covid-19 vaccine

Sources further added that there were no plans for any emergency-use authorisation of the Sputnik V without relevant and convincing local data

Covid-19: Dr Reddy's to distribute Russian vaccine in India. What we know

While Dr Reddy's Labs is preparing for clinical trials of Sputnik V, major manufacturers in the country are sceptical about the drug

Covid-19: Mass production of Sputnik V likely to take several months

Vaccine makers here feel the Sputnik is still a work in progress and needs time to develop

Top headlines: Dr Reddy's to get Russia vaccine, airlines' Q1 revenue dips

Business Standard brings you the top headlines of the day